jasdooit

Samsung is moving forward with a financial commitment to Arbor Biotechnologies (Arbor Bio), a U.S.-based firm focused on gene-editing innovations.

The initiative seeks to investigate promising new business ventures and work together on research concerning fundamental gene-editing techniques.

On the 30th, Samsung revealed that it plans to invest in Arbor Bio via its venture capital initiative known as the “Life Science Fund,” which was created jointly by Samsung C&T, Samsung Biologics, and Samsung Bioepis. The specific investment figure remains undisclosed.

Arbor Bio is a biotechnology startup that has developed gene-editing tools able to identify and cut specific genetic sites, as well as add, remove, alter, or replace particular genes. This innovation is applied in the treatment and prevention of multiple conditions, such as genetic diseases that are currently untreatable, blood-related issues, cancer, and inherited disorders.

Significantly, Samsung stated that Arbor Bio has developed optimized enzymes with diverse sizes and functions using AI and machine learning-driven predictive methods along with rapid experimental validation. This allows for the modification of most human genomes. Gene-editing technology is utilized in the treatment and prevention of genetic untreatable diseases, blood-related disorders, cancer, congenital conditions, and various other ailments.

Kim Yoon-cheol, Managing Director of Samsung Bioepis’ Enable Team, said, “Gene editing is a fundamental technology for addressing genetic disorders,” and noted, “Arbor Bio is a firm with significant knowledge and future potential in gene-editing advancements and has a strong likelihood of becoming a major player in this area.”

The Life Science Fund, which is overseen by Samsung Venture Investment, has been making investments since 2022 in fields including gene therapy, antibody-drug conjugates (ADCs), blood protein analysis technology, protein drug development utilizing generative AI, and gene-editing technology.